HUTCHMED's HMPL-A830 trial registry posted, detailing 147-participant Phase I/IIa design
The NCT07718581 registry record for HUTCHMED's KRAS-EGFR conjugate HMPL-A830 confirms trial structure, sites and eligibility criteria following the drug's Phase Ia dosing start.
HUTCHMED's lead update centers on the clinicaltrials.gov record for its newly dosed HMPL-A830 program, which adds detail beyond the earlier trial-start and licensing announcements.
- The registry confirms HMPL-A830 is being studied in a first-in-human, multicenter, open-label, phase I/Ⅱa clinical study of HMPL-A830 in participants with histologically or cytologically confirmed, unresectable, advanced, or metastatic solid tumors, who are refractory or progressed on/after available standard treatment.1 The trial is split into a Dose Escalation Part A (Phase I), enrolling approximately 57 participants, and a Dose Optimization Part B (Phase IIa), enrolling approximately 90 participants1, for a total estimated enrollment of 147.
- Part A aims to evaluate the safety, tolerability, and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for optimization (RDO) of HMPL-A830 in previously treated participants with solid tumors1, while Part B is designed to characterize the safety, tolerability, and preliminary efficacy of HMPL-A830 at RDO(s) to determine recommended dose(s) for phase 2 (RP2D) or phase 3 (RP3D) in participants with selected solid tumors1.
- Primary outcomes include dose-limiting toxicities, treatment-emergent adverse events, Objective Response Rate (ORR) assessed by investigators according to RECIST 1.1, and recommended doses for phase II or III studies (RP2D or RP3D)1, with the RP2D/RP3D selection to draw on determination of MTD achieved during the dose escalation part, safety data obtained across all different doses tested, tolerability data, PK data and efficacy data1.
- The study is listed as recruiting across 14 sites in 2 countries: United States, China1, though most individual sites, including University of California Irvine Medical Center and several China locations, are marked "not yet recruiting," with only Beijing Cancer Hospital listed as recruiting.
- Estimated timelines show primary completion on 2029-05-23 and study completion on 2029-12-15, according to the registry, consistent with the Phase Ia dosing start on September 24, 2026, previously reported following HUTCHMED's licensing agreement with a GSK subsidiary covering territories outside Mainland China, Hong Kong, Macau and Taiwan.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.